Halozyme Blocks Merck Keytruda in Europe
A Dutch patent court ruled in favor of Halozyme and ordered Merck to halt sales of its injectable Keytruda across eight European markets. Merck strongly disagrees with the decision and is evaluating its next steps.
Xurve View
Insights:
Xurve View